Table 4a. Nonhematologic adverse events.
| Adverse Events | Total (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| Hyperglycemia | 20 (95%) | — | 10 (48%) | 10 (48%) | — |
| Insomnia | 16 (76%) | 14 (67%) | 2 (10%) | — | — |
| Fatigue | 12 (57%) | 8 (38%) | 4 (19%) | — | — |
| Infusion reaction | 11 (52%) | 5 (24%) | 6 (29%) | — | — |
| Rash | 11 (52%) | 9 (43%) | 2 (10%) | — | — |
| Upper respiration infection | 11 (52%) | 4 (19%) | 7 (33%) | — | — |
| Hypokalemia | 9 (43%) | 8 (38%) | 1 (5%) | — | — |
| Anxiety | 8 (38%) | 7 (33%) | 1 (5%) | — | — |
| Arrhythmia | 7 (33%) | 5 (24%) | 1 (5%) | 1 (5%) | — |
| Elevated ALT (SGPT) | 7 (33%) | 6 (29%) | 1 (5%) | — | — |
| Hypocalcemia | 7 (33%) | 5 (24%) | 1 (5%) | 1 (5%) | — |
| Abdominal pain | 6 (29%) | 5 (24%) | 1 (5%) | — | — |
| Back pain | 6 (29%) | 5 (24%) | 1 (5%) | — | — |
| Allergic rhinitis | 4 (19%) | 2 (10%) | 2 (10%) | — | — |
| Hyperkalemia | 3 (14%) | 2 (10%) | 1 (5%) | — | — |
| Weakness | 3 (14%) | 2 (10%) | 1 (5%) | — | — |
| Weight gain | 3 (14%) | 2 (10%) | 1 (5%) | — | — |
| Cough | 2 (10%) | 1 (5%) | 1 (5%) | — | — |
| Hyperhidrosis | 2 (10%) | 1 (5%) | 1 (5%) | — | — |
| Pneumonia | 1 (5%) | — | — | 1 (5%) | — |
| Influenza | 1 (5%) | — | — | 1 (5%) | — |
| Kidney stone | 1 (5%) | — | — | 1 (5%) | — |
| Myocardial infarction | 1 (5%) | — | — | 1 (5%) | — |
| Squamous cell skin cancer | 1 (5%) | — | — | 1 (5%) | — |
Abbreviation: ALT, alanine aminotransferase; SGPT, serum glutamate pyruvate transaminase.